These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Antibiotic Tolerance Indicative of Persistence Is Pervasive among Clinical Streptococcus pneumoniae Isolates and Shows Strong Condition Dependence. Geerts N; De Vooght L; Passaris I; Delputte P; Van den Bergh B; Cos P Microbiol Spectr; 2022 Dec; 10(6):e0270122. PubMed ID: 36374111 [TBL] [Abstract][Full Text] [Related]
5. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae. Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae. Jones RN; Fritsche TR; Sader HS Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501 [TBL] [Abstract][Full Text] [Related]
8. Reactive Oxygen Species Contribute to the Bactericidal Effects of the Fluoroquinolone Moxifloxacin in Streptococcus pneumoniae. Ferrándiz MJ; Martín-Galiano AJ; Arnanz C; Zimmerman T; de la Campa AG Antimicrob Agents Chemother; 2016 Jan; 60(1):409-17. PubMed ID: 26525786 [TBL] [Abstract][Full Text] [Related]
9. Antibacterial activity of a DNA topoisomerase I inhibitor versus fluoroquinolones in Streptococcus pneumoniae. Valenzuela MV; Domenech M; Mateos-Martínez P; González-Camacho F; de la Campa AG; García MT PLoS One; 2020; 15(11):e0241780. PubMed ID: 33141832 [TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone. Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477 [TBL] [Abstract][Full Text] [Related]
11. [Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates]. Zhang FF; Zhao CJ; Wang H Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):940-4. PubMed ID: 24503427 [TBL] [Abstract][Full Text] [Related]
12. In vitro selection of resistance in Streptococcus pneumoniae at in vivo fluoroquinolone concentrations. De Vecchi E; Nicola L; Ossola F; Drago L J Antimicrob Chemother; 2009 Apr; 63(4):721-7. PubMed ID: 19218275 [TBL] [Abstract][Full Text] [Related]
13. Resistance of Streptococcus pneumoniae to fluoroquinolones--United States, 1995-1999. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2001 Sep; 50(37):800-4. PubMed ID: 11785571 [TBL] [Abstract][Full Text] [Related]
14. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test. Ramakrishnan R; Ramesh S; Bharathi MJ; Amuthan M; Viswanathan S Indian J Pathol Microbiol; 2010; 53(2):276-80. PubMed ID: 20551532 [TBL] [Abstract][Full Text] [Related]
15. Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004). Deshpande LM; Sader HS; Debbia E; Nicoletti G; Fadda G; Jones RN; Diagn Microbiol Infect Dis; 2006 Mar; 54(3):157-64. PubMed ID: 16423493 [TBL] [Abstract][Full Text] [Related]